What is BLCO's market cap?

$7.12B, based on the Nov 5 close of $19.92.

Does Bausch + Lomb pay a dividend?

No regular cash dividend has been paid in the last year.

How much of BLCO is sold short?

2.5M shares, 5.5% of float, as of Oct 15, 2026.

What sector is BLCO in?

Healthcare, in the Ophthalmic Goods industry.

NYSE · BLCOHealthcareOphthalmic Goods

Bausch + Lomb Corporation (BLCO)

$19.92−3.30%

Close Nov 5, 2026 · split-adjusted

Nov 4, 2026$20.60▲ 37.33% in range

Nov 4, 2025Low $14.56 · High $20.60Nov 4, 2026

What changed · written from our data

As of Nov 5, 2026

Bausch + Lomb closed at $19.92 on Nov 5, down 3.30%, 3.3% below its 52-week closing high. Volume of 699.4K shares was 0.65× its 20-day average (below normal).

Split-adjusted performance: +14.9% over one month, +25.2% over six months, +32.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.38B, up 7.3% from a year earlier, with a net margin of 2.3%.

Short interest was 2.5M shares at the Oct 15 settlement, down 14.0% from the prior report (5.5% of float, 3.6 days to cover).

Market cap$7.12B357.5M shares

Revenue · quarter$1.38B+7.3% YoY

Diluted EPS$0.09—

P/E · TTM—P/S 1.3×

Net margin2.3%Gross 64.7%

Dividend yieldNone

52-week range14.56 – 20.60−3.3% from high

Volume699.4K0.65× 20-day avg

Volatility · 60d39.8%Annualised

Short % of float5.5%3.6 days to cover

Net cash-$4.58BCash $513.0M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.4%1M +14.9%3M +18.7%6M +25.2%YTD +16.6%1Y +32.8%3Y +23.4%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Ophthalmic Goods

Percentile among 7 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −4.1%, revenue growth +2.5%, net margin 2.3%, P/E 222.2×.

Short interest

Details →

Shares short2.5M−14.0% vs prior

Days to cover3.6Settled Oct 15

% of float5.5%

Short vol. 10d32.2%of daily volume

Closest peers by size in Ophthalmic Goods

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
BLCOBausch + Lomb	$19.92	−3.30%	+25.2%	+7.3%	2.3%	—	$7.12B
COOThe Cooper Companies	$63.51	−1.41%	+3.9%	+0.6%	40.6%	21.2	$12.08B	Compare
WRBYWarby Parker	$26.08	+22.50%	−4.1%	+9.8%	2.0%	416.4	$3.22B	Compare
EYENational Vision Holdings	$17.85	−0.50%	−21.8%	+2.5%	2.5%	28.1	$1.41B	Compare
STAAStaar Surgical Co	$26.72	−1.66%	−2.1%	−12.0%	6.7%	2,528.0	$1.34B	Compare
RXSTRxSight	$4.54	−9.02%	−21.7%	−19.0%	−66.2%	—	$190.4M	Compare
LUCYInnovative Eyewear	$0.8210	−2.69%	−21.8%	+74.5%	−165.3%	—	$7.2M	Compare

News about Bausch + Lomb

All news →

Bausch + Lomb: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 1d ago▲ Positive Why Bausch + Lomb (BLCO) Might be Well Poised for a SurgeZacks Investment Research · 1d ago▲ Positive Why Bausch + Lomb (BLCO) is a Top Momentum Stock for the Long-TermZacks Investment Research · 1d ago▲ Positive BLCO vs. HQY: Which Stock Is the Better Value Option?Zacks Investment Research · 2d ago▲ Positive BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond LaserZacks Investment Research · Sep 14, 2026▲ Positive

Quick answers

What does Bausch + Lomb do?: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022.
What is BLCO's market cap?: $7.12B, based on the Nov 5 close of $19.92.
Does Bausch + Lomb pay a dividend?: No regular cash dividend has been paid in the last year.
How much of BLCO is sold short?: 2.5M shares, 5.5% of float, as of Oct 15, 2026.
What sector is BLCO in?: Healthcare, in the Ophthalmic Goods industry.

About Bausch + Lomb

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.

HQ: Vaughan, A613,000 employeesListed May 6, 2022bausch.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology